Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€182.50

€182.50

0.700%
1.25
0.700%
€302.51
 
19.04.24 / Tradegate WKN: 789617 / Symbol: BIIB / Name: Biogen / Stock / Pharmaceuticals / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Biogen Inc. Stock

Biogen Inc. gained 0.700% compared to yesterday.
The stock is one of the favorites of our community with 42 Buy predictions and 1 Sell predictions.
With a target price of 302 € there is a hugely positive potential of 65.48% for Biogen Inc. compared to the current price of 182.5 €.
So far the community has only identified positive things for Biogen Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".

Pros and Cons of Biogen Inc. in the next few years

Pros
?
S********** s********
?
C******** o* t** e**********
?
B****
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Biogen Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Biogen Inc. 0.700% -2.066% -9.384% -31.597% -22.604% -18.381% -9.452%
Pfizer Inc. 2.180% 0.308% -4.165% -33.633% -6.552% -24.606% -26.614%
Elanco Animal Health Inc. -6.370% -9.960% -15.859% 40.625% -10.133% -51.439% -
AbbVie Inc. 0.570% 2.373% -5.448% 6.114% 11.492% 73.056% 125.429%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-06-27

Upon initial examination, Biogen's financial health appears to be quite stable. The company demonstrates significant total assets backed by a strong shareholder equity. However, it's also essential to dig deeper into the financial landscape of this key player in the pharmaceutical industry to understand its true standing.

Strong Gross Profit: Biogen has consistently reported solid gross profits over the years. This is a positive sign as it indicates effective operations and significant markup on products, a crucial aspect of success within the pharmaceutical industry.

Substantial Assets and Equity: The company boasts noteworthy total assets and shareholder equity. This indicates that Biogen is well-capitalized and has substantial resources at its disposal to facilitate growth and tactical maneuvers in the market.

Comments

Biogen Inc. (NASDAQ: BIIB) had its "outperform" rating re-affirmed by analysts at William Blair.
Ratings data for BIIB provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -8.52%
Target price 313.718
Change
Ends at 25.03.25

Biogen Inc. (NASDAQ: BIIB) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $340.00 price target on the stock.
Ratings data for BIIB provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -9.47%
Target price 334.734
Change
Ends at 05.03.25

Biogen Inc. (NASDAQ: BIIB) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $364.00 price target on the stock.
Ratings data for BIIB provided by MarketBeat
Show more

News

1 Wall Street Analyst Thinks Biogen Stock Is Going to $311. Is It a Buy Around $223?: https://g.foolcdn.com/editorial/images/767026/scientist-works-at-lab-bench.jpg
1 Wall Street Analyst Thinks Biogen Stock Is Going to $311. Is It a Buy Around $223?

On Feb. 20, Cantor Fitzgerald analyst Eric Schmidt restated his aggressive price target for Biogen, (NASDAQ: BIIB) estimating that the biopharmaceutical stock will rise by 39% to reach roughly $311

Biogen (BIIB) Q4 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg
Biogen (BIIB) Q4 2023 Earnings Call Transcript

Image source: The Motley Fool.

Biogen (NASDAQ: BIIB)Q4 2023 Earnings CallFeb 13, 2024, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

Why Eli Lilly Stock Could Start Off 2024 With a Bang: https://g.foolcdn.com/editorial/images/759509/businessperson-giving-a-presentation.jpg
Why Eli Lilly Stock Could Start Off 2024 With a Bang

Eli Lilly (NYSE: LLY) has been one of the hottest healthcare stocks to own in recent years. The company is now the most valuable healthcare company in the world, with a valuation of around $550